ROLE OF 1-INTEGRIN EXPRESSION IN TRASTUZUMAB RESISTANCE IN RADIATION INDUCED HER-2-POSITIVE BREAST CANCER

被引：0
|
作者：
Thoms, J. [1 ]
Sabri, S. [1 ]
Lesniak, D. [1 ]
Murray, D. [1 ]
Abdulkarim, B. [1 ]
机构：
[1] Cross Canc Inst, Edmonton, AB, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [21] Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
    Pascual-Mathey, Luz I.
    Velez-Figueroa, Midory I.
    Diaz-Vallejo, Joel J.
    Mendez-Hirata, Gustavo
    Mendez-Machado, Gustavo F.
    REPORTS, 2024, 7 (03)
  • [22] Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer
    Roy, Vivek
    Perez, Edith A.
    ONCOLOGIST, 2009, 14 (11): : 1061 - 1069
  • [23] Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance
    Tehfe, Mustapha
    Tabchi, Samer
    Laterza, Maria Maddalena
    De Vita, Ferdinando
    FUTURE ONCOLOGY, 2018, 14 (03) : 223 - 228
  • [24] Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Pusztai, L
    Esteva, FJ
    CANCER INVESTIGATION, 2006, 24 (02) : 187 - 191
  • [25] Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
    Browne, B. C.
    Crown, J.
    Venkatesan, N.
    Duffy, M. J.
    Clynes, M.
    Slamon, D.
    O'Donovan, N.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 68 - 73
  • [26] Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs
    Suleman, Kausar
    Mushtaq, Ali Hassan
    Haque, Emaan
    Badran, Ahmed Ali
    Ajarim, Dahish
    Elashwah, Ahmed Mohammed
    Gad, Ahmed Mostafa
    Abdelsamad, Amgad Shaheen
    Omar, Ayman
    Khan, Khurshid Ahmed
    Al-Tweigeri, Taher
    Elshentenawy, Ayman
    Alsayed, Adher
    BREAST CARE, 2021, 16 (01) : 59 - 65
  • [27] Clinical utility of continuing trastuzumab beyond brain progression in HER-2-positive metastatic breast cancer
    Metro, Giulio
    Sperduti, Isabella
    Russillo, Michelangelo
    Milella, Michele
    Cognetti, Francesco
    Fabi, Alessandra
    ONCOLOGIST, 2007, 12 (12): : 1467 - 1469
  • [28] Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer
    Bullock, Karen
    Blackwell, Kimberly
    ONCOLOGIST, 2008, 13 (05): : 515 - 525
  • [29] Expression of hormone receptors ERα, ERβ and PgR in HER-2-positive breast cancer
    Litwiniuk, Maria
    WSPOTCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (05): : 235 - 239
  • [30] HER-2-Positive breast cancer - Hope beyond trastummab
    Bartsch, Rupert
    Wenzel, Catharina
    Zielinski, Christoph C.
    Steger, Guenther G.
    BIODRUGS, 2007, 21 (02) : 69 - 77
12345